Geron Corporation (GERN) - News Archive

Recent notices issued by The Gross Law Firm and Levi & Korsinsky, LLP indicate that Geron Corporation (NASDAQ: GERN), a company specialized in developing therapies for cancer treatment, finds itself embroiled in class a...

In recent developments, Geron Corporation (NASDAQ: GERN) has caught the attention of investors and legal analysts alike due to a notice issued by The Gross Law Firm, urging shareholders to contact them before May 12, 20...

On May 12, 2025, the deadline will arrive for investors in Geron Corporation (NASDAQ: GERN) to join a class action lawsuit against the biotechnology firm. As the company navigates complex market conditions, shareholders...

In a significant development within the biotech sector, Geron Corporation, a noted leader in the development of therapies for hematologic malignancies, has recently become the focal point of a class action lawsuit. On A...

In a significant development for investors in Geron Corporation (NASDAQ: GERN), a class action lawsuit has been filed against the company and certain officers, raising critical questions regarding corporate governance,...

In a significant legal development, Pomerantz LLP has announced the filing of a class action lawsuit against Geron Corporation (NASDAQ: GERN) and certain company officers. This lawsuit was initiated in the United States...

In recent months, investors in Geron Corporation (NASDAQ: GERN) have found themselves at a critical juncture as the company faces a securities class action lawsuit. The Rosen Law Firm, known for its commitment to protec...

This article examines the financial status of Geron Corporation with an emphasis on their current class action lawsuit and leverage ratios. It assesses the implications of rising debts and class action litigation, offer...

Understanding the Implications of the Geron Corporation Securities Class Action: A Call to InvestorsIn the complex world of biotechnology and pharmaceuticals, legal challenges can arise unexpectedly, influencing both ma...

In a significant boost for both Geron Corporation and patients suffering from lower-risk myelodysplastic syndromes (MDS), the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Revolutionizing Blood Cancer Treatment: Geron Corporation’s Breakthrough with RYTELO (Imetelstat) in Lower-Risk Myelodysplastic Syndromes In the constantly evolving field of oncology, breakthroughs are hard-won and tran...

: Geron Corporation, a Nasdaq-listed commercial-stage biopharmaceutical company, recently announced the release of several abstracts highlighting new findings related to RYTELO (imetelstat), a pioneering telomerase inhi...

As the landscape of blood cancer treatment continues to evolve, Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company based in Foster City, California, is making significant strides with its lat...

Geron Corporation’s Game-Changer: NCCN Endorsement for RYTELO In a significant development for the biopharmaceutical sector, Geron Corporation (Nasdaq: GERN) has secured an updated endorsement from the National Comprehe...

Groundbreaking Developments: NCCN Guidelines Update and FDA Approval Endorse RYTELO (Imetelstat) for Treatment of Symptomatic Anemia in Lower-Risk MDS Patients FOSTER CITY, Calif. - Geron Corporation (Nasdaq: GERN), a c...

Geron Corporation Takes Major Steps Forward in Treating Myelodysplastic Syndromes with RYTELO (Imetelstat) Foster City, California - Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company focused...

: Geron Corporation s RYTELO (imetelstat) has received updated recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Oncology concerning its use in treating symptomatic ane...

In a significant development for patients with myelodysplastic syndromes (MDS), Geron Corporation has announced the FDA approval of RYTELO (imetelstat). This groundbreaking telomerase inhibitor has been approved for the...

Foster City, CA based Geron Corporation (Nasdaq: GERN), a leading company at the forefront of biopharmaceutical research and late-clinical-stage developments, has released its financial results and business highlights f...